Abstract: INTRODUCTION: Basal cell carcinoma (BCC) is the most frequent cancer with increasing incidence over the last decades. Standard of care is surgical excision, upon which complete tumour clearance is achieved in most cases. However, a small subgroup of patients will have remnants of disease post-excision and require further treatment options. Over 90% of all BCCs carry a mutation in PTCH 1 or SMO, two conducting proteins of the Hedgehog pathway (Hh). Therefore, inhibition of the Hh pathway is a promising option for systemic first-line therapy. Vismodegib was the first developed of these small molecules, which was approved by the FDA in January 2012. AREAS COVERED: The authors review current treatment modalities for BCC and discuss current developments in pharmacological therapy. The current literature including meta-analyses, the Cochrane database and registered as well as completed randomized controlled trials. EXPERT OPINION: Hh inhibitors are a new promising treatment option for patients with advanced or metastatic BCC. Phase I and II clinical trials with the Hh inhibitor, vismodegib, showed a significant reduction in tumour size and appearance of new tumours with relatively good tolerability. Nevertheless, further investigation on new molecules and the effectiveness of an intermittent dosing regimen is necessary. 
Epidemiology
Basal cell carcinoma (BCC) is the most frequently diagnosed skin cancer and most common cancer in humans of European ancestry with increasing rates of incidence 1 . It comprises approximately 70% of all cutaneous cancers in Europe. Reliable data of the précis incidence are rare due to unsystematic documentation of diagnoses. However, the cancer registery for
West-Switzerland has clearly documented an ongoing increase in incidence in males from 70 / 100'000 per year in 1980's to 140 / 100'000 per year in 1990's with continuing trend.
According to these data, estimated lifetime risk for BCC development in the collective of newborn children in Switzerland in the year 2000 is at least 1:10 2 . BCC causes considerable morbidity and is one of the most expensive cancers to the health care managing systems 3 .
Aetiological risk factors and Pathobiology
The overall lifetime risk for BCCs is estimated to be approximately 30%. The risk of development increases with age reaching its peak during 6th -8th decades. The incidence is higher in males than in females. The history of at least one BCC bears a cumulative risk of more than 40% for developing further BCCs within the next 3 years. This suggests genetic alterations -besides pre-existence of other risk factors 4 .
The most important exogenous risk factor is exposure to ultraviolet (UV) radiation. Genotoxic damages induced by UV-B radiation (290 -315 nm wavelength) [5] [6] [7] is linked to the history of multiple sun burns in early ages and intensive intermittent sunlight exposure 8, 9 . The incidence of BCC is non-linearly correlated to the total UV exposure with peak at approximately two fold at 10,000-35,000 hours total sun exposure and remaining stable rates with additional exposure 10, 11 .
Accordingly, lifestyle-related usage of indoor tanning and sun seeking behaviour might explain data showing increased incidence rates of BCC in younger population and women 12 .
Further risk factors are frequent x-ray irradiation 13, 14 and arsenic exposure 15 with known mutagenic effects on genes such as p53. Additionally, the combination of arsenic and UV radiation enhances UV induced genotoxic damages by arsenic and its metabolite [16] [17] [18] [19] .
Iatrogenic immunosuppression -particularly in organ transplant recipients -is another risk factor for BCC development depending on duration and dosage of immunosuppressants 20 . In immunocompromised population either caused iatrogenic or diseases such as AIDS, lymphoma or leukaemia BCC occur more often, in multiple numbers, aggressive forms and unusual locations [21] [22] [23] .
One of the most important genetic risk factor is fair skinned type I-II 24 ,which is based on the presence of melanin subtypes phaeomelanin (red-yellow pigment) and eumelanin (brownblack pigment) that have protective role against UV radiation. In patients with albinism there the lack of melanin production due to mutation in the TYR gen, which results in increased photosensitivity and enhanced risk for developing BCCs, SCCs and melanoma 25 . In case of variations of the melanocortin 1 receptor gene /MC1) that encodes the receptor for α-melanocyte-stimulating hormone (αMSH), which is responsible for the switch between eumelanin and phaeomelanin and determining the intensity of skin pigmentation 26 , the risk for developing BCC is increased 27, 28 .
Mutations of tumour suppressor genes such as p53 and patched homologue 1 (PTCH1) are observed in more than 90% of BCCs and have been proven to be essential for its pathogenesis [28] [29] [30] . BCCs are common early in life in patients with hereditary syndromes such as the Gorlin-Goltz-syndrome 31 , Xeroderma pigmentosum 32, 33 24 , Rombo-syndrome 34 or BazexDupré-Christol-syndrome 35 . Patients who are affected by those syndromes, present BCCs already in early childhood [36] [37] [38] . Sunscreens use by patients with history of BCC, showed that the number of p53 mutations in tumours decreases upon UV protection underscoring the importance of consequent UV protection, especially in these patients 39 .
Most of basal cell carcinomas occur sporadically. 
Hedgehog Pathway
Hedgehog (Hh) signalling pathway is a driving force of carcinogenesis with mutations found in more than 70% of sporadic BCC 47, 48 , and 20-30% of medulloblastoma 49, 50 .
The Hh pathway was initially discovered in Drosophila melanogaster 51 . This pathway is important for the embryonic development and differentiation of the cells.
In adults, the Hh pathway is turned off in normal cells, except the cells hair, skin and stem cells 52 .
Hh signalling pathway entitled after the family of extracellular Hh ligands, includes several molecules that have ability mutually control their activity. The Hh family of protein ligands consists of three members: Sonic Hedgehog (SHh), Desert Hedgehog (DHh) and Indian Hedgehog (IHh) with capability to bind to PTCH (Figure 1 Besides PTCH, suppressor of fused (SUFU) was verified as negative regulator of Hh pathway by inhibiting Gli1 and Gli2 from entering the nucleus and converting Gli into its repressor form (GliR) with consecutive function as transcriptional repressor on the Gli target genes.
In contrast, activated Gli (GliA) is associated with changes in transcription which leads to cell proliferation and differentiation 55, 56 . In addition, Smo accumulation relieves the suppression exerted by SUFU on the Gli transcription factors. Accordingly, inactivation of inhibitors PTCH1 or SUFU, caused by either mutation or otherwise degradation, as well as activation of Smo lead to Hh pathway activation 57 .
Clinical and histological aspects of BCCs
The cell of origin in BCCs with its importance for pathogenesis and further development of In a sBCC prospective randomized multicenter trial, photodynamic therapy (MAL-PDT) demonstrated a better cosmetic outcome with similar high efficacy compared to surgery 68 .
Radiotherapy using superficial x-rays or electrons is a suitable alternative especially in patients of advanced age (>60 years), anatomically critical localizations such as the periorbital region or or when surgery is contraindicated. . 2 Nethertheless, radiotherapy is not suitable for morphoeic or desmoplastic BCC due to the high risk of recurrence 65 .
Chemotherapy

5-Fluorouracil (5-FU)
5-FU is a pyrimidine analogue that inhibits the enzyme thymidylate synthase and thereby prevents DNA synthesis in tumor cells. In multiple superficial low risk, extrafacial BCCs or in patients with Basalcell naevus syndrome, topical 5-FU treatment can be contemplated. 
Targeted therapies on Hh Pathway
Cyclopamine
The first well studied targeted therapy of the Hh pathway, was cyclopamine, an endogenous steroidal plant alkaloid derived from corn lilies 75 . Cyclopamine competitively inhibits Smo by binding directly to the transmembrane domain of the protein. This induces midline deformities in embryogenesis 76 and leads to growth inhibition in malignant cells 75, 77 .
Already in 2004, there was a report on the topical use of this inhibitor in few BCC patients.
All of them experienced clinical improvement with histological tumour regression attributed to induction of apoptosis 78 .
Consequently, synthetic Cyclopamine derivates were developed to optimize the inhibitory effects on the Hh signaling and encouraged elaboration of small molecule antagonist of Smo were found (e.g. GDC-0449, LDE225). The most promising specific Hh inibitor was Vismodegib (GDC-0449, Genentech), for which could be shown to have efficacy in patients with medulloblastoma 51 .
Vismodegib
Vismodegib ( 
Itraconazol
The systemic antifungal drug itraconazol, an azol derivate that inhibits biosynthesis of There was hardly any inflammation. 3 out of 13 with LDE 225 treated BCCs showed a complete remission and 9 a partial remission clinically. However, histological investigations still showed remaining tumour nests that presented with reduced proliferation as assessed immunohistochemical by using expression of ki67 86 .
LEQ 506 and other smoothened inhibitors
The efficacy and tolerance of further substances such as PI-926, BMS-838923 (XL139), TAK-441, PF-04449913 and LEQ, are currently explored in phase I and II trials for patients with BCCs as well as in patients with medulloblastoma or other cancerse.g. 506 85 . The results of these studies are currently not available.
. An ongoing phase II study in pediatric patients from 3 to 21 year old patients with medulloblastoma are treated with vismodegib
87
. Data on geriatric patients are limited so far.
So far no phase III trials have been initiated for Hh inhibitors due to the fact of missing compareable treamtents.
Highlight Box
• Basal cell carcinomas (BCC) are the most frequent cancer in human beings and standard of care is the surgical excision.
• Over 90% of all BCC have a mutation in PTCH 1 or SMO, two conducting proteins of the Hedgehog pathway.
• Hedgehog inhibitors are a new option for a systemic treatment for locally advanced or metastatic BCC.
• Vismodegib was the first drug to be approved by the FDA.
• The most side effects are mild and overall well tolerated.
Side effects
Von Hoff et al. reported no grad 5 adverse events and only one grade 4 event was seen (asymptomatic hyponatremia). Several grade 3 events have been reported: fatigue, hyponatremia, weight loss, dyspnea, muscle spasm, atrial fibrillation, aspiration, back pain, corneal abrasion, dehydration, keratitis, lymhopenia, pneumonia, urinary tract infection and prolonged QT interval for vismodegib 88 .
1 out of 33 patients decided to discontinue the treatment after 8 months because of ongoing grade 1 adverse events (abdominal pain, fatigue, weight loss, dysgeusia) and grade 2 anorexia.
In the study of Sekulic et al., all 104 patients had at least one adverse event 89 . 57% showed grade 1 and 2 events , which was consistent with those from the phase I study. Grade 3 and 4 adverse events included muscle spasms, weight loss, fatigue and loss of appetite ( Table 2) .
25% of the events were considered serious adverse events and 7 patients experienced grade 5 events (including death from unknown cause, hypovolemic shock, myocardial infarction, meningeal disease and ischemic stroke). The relationship of these fatal events and
Vismodegib are unknown as they showed no definite pattern and all patients had clinically significant risk factors or coexisting conditions at baseline.
About half the patients had discontinued the study at a median treatment duration of approximately 10 months. 18% in the metastatic BCC group because of disease progression and in the other cohort 25% of the patients decided to stop the treatment on their own with to us unknown reasons.
Tang et al. observed mild or moderate adverse events and no grade 5 events 90 . Patients receiving Vismodegib had significantly more adverse events than patients on placebo.
Also in this study patients have withdrawn their consent due to adverse events. The ceased shortly after ending with vismodegib: dysgeusia and muscle cramps within 1 month and the regrowth of hair were observed within 3 months.
The adverse events of vismodegib are similar in all clinical trials done so far. The assumption is that they are mechanism-related.
Hair follicle growth is initiated by the WNT signaling that induces the formation of the dermal condensate 91 . For further development of the hair the Hedgehog pathway is required.
Chiang et al. could show in their experiments with mice that hair germs consist of epidermal placodes and associated dermal condensates and are found in both, the control and the Shh -/-embryos. For the progression in the further development of the hair follicle the Sonic Hedgehog is needed and therefore this process is blocked in mutant skin 92 .
Furthermore, these rudimental hair follicles are capable of a localized growth and differentiation, but unable to form a normal hair . That led to an ineffective binding of vismodegib 51 96 .
Further research on the mechanism of resistance was performed by Dijkgraaf et al. They could proof that a modified SMO with an exchange of the amino acid aspartic acid at position 473 resulted in a less sensitive binding of vismodegib than wild-type SMO 97 . In addition they determined that mutation in E518 of SMO leads to a complete resistance of SMO to vismodegib. The amplification of GLI2 downstream of SMO was another mechanism of resistance to vismodegib 97 .
Itraconazol, a systemic azole antifungal agent, was recently detected to inhibit SMO in the Hh signaling pathway, but with another mechanism than the one of cyclopamine and with a less significantly potency than the currently available Hh inhibitors 84 . According to the resistance by amplification of GLI2 it is also supposable to block the GLI function to overcome resistance. One such substance in development is GANT61 98 . The identification of secondgeneration SMO antagonists that show efficacy in SMO-Wildtype as well as SMO-mutants may be another suitable way to overcome resistance 97 .
Another potential resistance mechanism is the up-regulation of the phosphoinoditide 3-kinase (PI3K) pathway. It was detected that in NVP-LDE225-resistant samples (a new potent and selective oral SMO inhibitor from a newly described structural class 99 . IGF1R-PI3K target genes were much upregulated comparing to drug-sensitive samples 100 . This implicates that the PI3K pathway is involved in the resistance mechanism of the Hh pathway. Targeting the PI3K pathway may provide a suitable solution in the situation of Hh resistance. First encouraging results have been shown by Engelman et al. 101 .
So far there are no proven salvage therapies available to overcome acquired Hedgehog resistance, but the above mentioned ways are all promising approaches to therapy and need further investigation.
Conclusion
A careful analysis of the molecular pathways has identified the Hedgehog signaling pathway In patients with a low tumor burden, the topical use of smoothened inhibitors should be explored in more detail. Early results have indicated some efficacy for this treatment, however there is no information on the histological clearing of the tumor cells and the optimal time and dosing of topically used smoothened inhibitors. This approach would definitely avoid the significant side effects, especially after long term treatment of this drug class.
In our opinion, smoothened inhibitors are essential in the repertoire of small molecules inhibitors. The importance of the Hedgehog signaling pathway in other malignancies is under investigation. 
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